Various approaches targeting the cytokine to the tumor, such as colloidal gold-bound TNF-α [272], gene transfer [273], recombinant TNF-α fused to an antibody anti-fibronectin of tumor endothelium (L19-TNF) [274], failed to reach significant results in clinical trials. The gene discussed is TNF; the disease is neoplasm.